oramed.com - נכסים נקיים למניה בודדת ORMP

Oramed Pharmaceuticals automates the synthesis of substances to create oral insulin, leveraging the expertise of scientists. The actual book value per share confirms the current trend, where the indicator remains at 7.74. Exclusive encapsulation patents create a formidable barrier to entry for competitors. Further growth is based on prudent capital management and the search for new promising bio-assets.

To minimize fundamental risks, investors utilize the calculation of residual capital per share, defined as the difference between all assets and liabilities of the issuer. By analyzing the book value per share, one can assess the actual resource volume of Oramed Pharmaceuticals (ORMP), which is critically important during a period of active startup sourcing for M&A integration and the utilization of existing cash reserves.